lated many efforts for their synthesis.4 The design concept
of the presently synthesized target has originated from the
recognition of the biological role of the dihydropyrimi-
dines and benzimidazoles which exhibits a wide range of
pharmacological properties5 including nociceptin/orpha-
nin FQ receptor agonism6 and HIV-1 integrase inhibition.7
Thus, the generation of a fused heterocyclic skeleton
resembling druglike molecules has a substantial intellec-
tual appeal and thus provoked us to synthesize benzimi-
dazolyl-fused dihydropyrimidines.
Scheme 2. Base-Catalyzed Povarov Reaction and
Rearrangement
Modern synergetic approaches integrating the soluble
polymer-supported synthesis with microwave synthesis
provides a powerful strategy to generate a diversified
molecular library to speed up initial drug discovery.8
Microwave heating greatly accelerates the rate of reac-
tions, while polymer support facilitates purifications by a
simple precipitation technique.9 Our laboratory is fasci-
nated by the application of such eco-friendly technologies
to develop rapid synthetic methods for biologically pro-
mising molecules.10 In continuation of our studies, here we
disclose an unprecedented base-catalyzed Povarov reac-
tion of heteroarylimines with electron-deficient dieno-
philes and subsequent unusual [1,3] sigmatropic rearrange-
ment and the development of a multicomponent strategy
toward the soluble support for synthesis of the dihydro-
pyrimido[1,2-a]benzimidazole library.
The most promising method to investigate the Povarov
reaction under basic conditions is to synthesize the aryli-
mine first and then treat it with various dienophiles. At the
outset of our studies, the viability of the imination was first
attempted by a reaction of 2-aminobenzimidazole 1a with
benzaldehyde 2a (optimization table provided in the Sup-
porting Information). The desired imine formation was
not observed under thermal reflux conditions in toluene,
using trifluoroacetic acid in dichloromethane and utilizing
scandium triflate as a Lewis acid catalyst in methanol,
chloroform, and toluene under reflux as well as microwave
conditions. However, use of the ammonium chloride in
toluene under thermal and microwave conditions affords
imine in moderate yields. Our investigation of the intended
base-catalyzed Povarov reaction led us to investigate
piperidine as a catalyst for imine preparation. The use of
piperidine (0.5 equiv) in toluene under microwave condi-
tions was found to provide the best results. Mechanisti-
cally, condensation of aldehyde with piperidine provides
the piperidinium hydroxide salt.11 The nucleophilic
addition of benzimidazol-2-amine 1a to piperidinium hy-
droxide salt with expulsion of water and a piperidine unit
affords benzimidazole-2-imine derivative 3a.
To investigate the Povarov reaction under basic condi-
tions, as a model reaction, it was decided to use methyl
propiolate as reactive dienophile and piperidine as a base
catalyst. Consequently, benzimidazole-2-imine 3a was
treated with methyl propiolate and piperidine in toluene
under microwave conditions at 120 °C. After 5 min,
benzimidazole-fused dihydropyrimidine was obtained as
a product, whose structure was considered as 4a according
to the anticipated results (Scheme 2).
Figure 1. ORTEP diagram and key NOE enhancements of 5a.
In addition to spectroscopic studies, additional 1D NOE
studies were carried out for the confirmation of structure
and regioselectivity of the resulting tricyclic heterocycle.
Peculiarly, the results of 1D NOE experiments did not
correspond to the structure of proposed Povarov reaction
product 4a. The irradiation of proton Ha in fused tricyclic
heterocycle enhances the signals of phenyl protons by
2.10%. However, the irradiation of Hb proton enhanced
the signals of phenyl proton by 4.79% as well as shows
enhancement of Hc proton by 2.90% (Figure 1). These
observations indicate that the phenyl group could be in
proximity of the Hb proton rather than the expected Ha
proton. With this ambiguity, the structure of the fused
(6) Hayashi, S.; Hirao, A.; Imai, A.; Nakamura, H.; Murata, Y.;
Ohashi, K.; Nakata, E. J. Med. Chem. 2009, 52, 610.
(7) Jones, E. D.; Vandegraaff, N.; Le, G.; Choi, N.; Issa, W.;
Macfarlane, K.; Thienthong, N.; Winfield, L. J.; Coates, J. A. V.; Lu,
L.; Li, X.; Feng, X.; Yu, C.; Rhodes, D. I.; Deadman, J. J. Bioorg. Med.
Chem. Lett. 2010, 20, 5913.
(8) Hsiao, Y. S.; Yellol, G. S.; Chen, L. H.; Sun, C. M. J. Comb.
Chem. 2010, 12, 723.
(9) (a) Zhang, W. Chem. Rev. 2009, 109, 749. (b) Presset, M.;
Coquerel, Y.; Rodriguez, J. Org. Lett. 2009, 11, 5706.
(10) (a) Chen, C. H.; Kuo, J.; Yellol, G. S.; Sun, C. M. Chem. Asian J.
2011, 6, 1557. (b) Yellol, G. S.; Chung, T. W.; Sun, C. M. Chem.
Commun. 2010, 46, 9170. (c) Lai, J. J.; Salunke, D. B.; Sun, C. M. Org.
Lett. 2010, 12, 2174.
(11) Correa, W. H.; Edwards, J. K.; McCluskey, A.; McKinnon, I.;
Scott, J. L. Green Chem. 2003, 5, 30.
Org. Lett., Vol. 13, No. 19, 2011
5121